- Global Pharma News & Resources

Mallinckrodt to Present at Raymond James Life Sciences and Medtech Conference

STAINES-UPON-THAMES, United Kingdom, May 31, 2019 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Wednesday, June 19, 2019, at the Raymond James Life Sciences and MedTech Conference at the Lotte New York Palace, 455 Madison Ave, New York. 

Bryan Reasons, Executive Vice President and Chief Financial Officer, Steven Romano, M.D., Executive Vice President and Chief Scientific Officer, and Hugh O'Neill, Executive Vice President and Chief Commercial Officer will represent the company in a fireside chat at 8 a.m. Eastern.  

Individuals who cannot attend the meeting in person can find webcast information at: A replay will also be available following the meeting.

Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reporting segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reporting segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.


Investor Relations
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO

Daniel Yunger
Kekst CNC

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2019 Mallinckrodt. 5/19


View original content to download multimedia:

SOURCE Mallinckrodt Pharmaceuticals

Mallinckrodt to Present at Raymond James Life Sciences and Medtech Conference

Editor Details

Last Updated: 31-May-2019